Zacks Research Issues Negative Outlook for Medifast Earnings

Medifast, Inc. (NYSE:MED) – Analysts at Zacks Research decreased their Q2 2025 earnings per share estimates for shares of Medifast in a research report issued on Monday, November 25th. Zacks Research analyst A. Mohta now expects that the specialty retailer will earn $0.29 per share for the quarter, down from their previous forecast of $0.37. The consensus estimate for Medifast’s current full-year earnings is $1.51 per share. Zacks Research also issued estimates for Medifast’s Q3 2025 earnings at $0.34 EPS, Q4 2025 earnings at $0.38 EPS, Q1 2026 earnings at $0.42 EPS and Q2 2026 earnings at $0.43 EPS.

Separately, DA Davidson upgraded Medifast from an “underperform” rating to a “neutral” rating and increased their price objective for the company from $16.50 to $17.00 in a report on Tuesday, November 5th.

Medifast Trading Up 6.1 %

MED opened at $19.44 on Wednesday. Medifast has a one year low of $17.07 and a one year high of $76.42. The company has a market cap of $212.67 million, a P/E ratio of 29.45 and a beta of 1.13. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.55 and a current ratio of 3.11. The business’s 50-day simple moving average is $18.49 and its 200-day simple moving average is $19.83.

Medifast (NYSE:MED) last issued its quarterly earnings results on Monday, November 4th. The specialty retailer reported $0.35 earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.50. Medifast had a return on equity of 15.98% and a net margin of 1.09%. The company had revenue of $140.16 million for the quarter, compared to the consensus estimate of $135.45 million. During the same quarter in the prior year, the business earned $2.12 EPS.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in MED. nVerses Capital LLC boosted its position in shares of Medifast by 54.5% in the 2nd quarter. nVerses Capital LLC now owns 1,700 shares of the specialty retailer’s stock valued at $37,000 after purchasing an additional 600 shares during the period. Centiva Capital LP boosted its position in shares of Medifast by 6.3% in the 3rd quarter. Centiva Capital LP now owns 15,238 shares of the specialty retailer’s stock valued at $292,000 after purchasing an additional 898 shares during the period. Quarry LP boosted its position in shares of Medifast by 592.7% in the 2nd quarter. Quarry LP now owns 2,667 shares of the specialty retailer’s stock valued at $58,000 after purchasing an additional 2,282 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of Medifast by 21.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 13,828 shares of the specialty retailer’s stock valued at $530,000 after purchasing an additional 2,472 shares during the period. Finally, Swedbank AB acquired a new stake in shares of Medifast in the 1st quarter valued at about $115,000. Hedge funds and other institutional investors own 95.51% of the company’s stock.

Medifast Company Profile

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.